Asante Solutions (PUMP) vs. Ocular Therapeutix (OCUL) Financial Analysis
Asante Solutions (NASDAQ: PUMP) and Ocular Therapeutix (NASDAQ:OCUL) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.
This table compares Asante Solutions and Ocular Therapeutix’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent ratings for Asante Solutions and Ocular Therapeutix, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Asante Solutions presently has a consensus target price of $18.70, indicating a potential upside of 44.40%. Ocular Therapeutix has a consensus target price of $24.00, indicating a potential upside of 280.35%. Given Ocular Therapeutix’s higher possible upside, analysts plainly believe Ocular Therapeutix is more favorable than Asante Solutions.
Valuation & Earnings
This table compares Asante Solutions and Ocular Therapeutix’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Asante Solutions||$666.25 million||1.61||$51.36 million||N/A||N/A|
|Ocular Therapeutix||$1.90 million||96.50||-$54.64 million||($2.13)||-2.96|
Asante Solutions has higher revenue and earnings than Ocular Therapeutix.
Institutional & Insider Ownership
53.4% of Ocular Therapeutix shares are owned by institutional investors. 26.1% of Ocular Therapeutix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Asante Solutions beats Ocular Therapeutix on 7 of the 12 factors compared between the two stocks.
Asante Solutions Company Profile
Asante Solutions, Inc. is a medical device company. The Company is a manufacturer of Asante Snap Insulin Pump System (Snap system), which is a pump featuring a modular design with pre-filled insulin cartridges and disposable pump bodies, utilized in combination with a controller. The Snap system comprises four components: the Snap system controller, a disposable pump body, disposable pre-filled insulin cartridges and disposable infusion sets. The Snap system also incorporates a technology that allows for auto-priming, whereby, without user intervention, the infusion tubing is automatically filled with insulin every time a new cartridge is inserted. The disposable pump body, which contains a fresh battery, is designed to be used for a week. The Company markets the Snap system through distributors of medical equipment and supplies to individuals with diabetes.
Ocular Therapeutix Company Profile
Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye. Its lead product candidates are DEXTENZA (dexamethasone insert), for the treatment of post-surgical ocular inflammation and pain, allergic conjunctivitis and dry eye disease, and OTX-TP, for the treatment of glaucoma and ocular hypertension, which are extended-delivery, drug-eluting inserts that are placed into the canaliculus through a natural opening called the punctum located in the inner portion of the eyelid near the nose. It also has an intravitreal hydrogel depot, which is in preclinical development for the treatment of diseases and conditions of the back of the eye, including wet age-related macular degeneration (wet AMD).
Receive News & Ratings for Asante Solutions Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asante Solutions Inc and related companies with MarketBeat.com's FREE daily email newsletter.